#PRCT

PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth PROCEPT BioRobotics (Nasdaq: PRCT) hosted its 2026 Investor Day outlining a multi-year plan to drive leadership in BPH with Aquablation therapy. Management projects 2026 revenue growth of 27%–33%, 2026 procedure growth of 39%–48%, and 2026 gross margin of 65%, improving to 68%–70% in 2027.The company expects positive adjusted EBITDA in Q4 2026 and a 2027 adjusted EBITDA gain of $25–30 million. WATER IV prostate cancer trial procedures are expected complete by mid-2026, and more than 125,000 patients have been treated to date.

2 weeks ago

#PRCT PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

Being Exponential | Luke Lango

@beingexponential.bsky.social

2 months ago

Actuators: #HSYDF #MOG.A
Power: #AMPX #ENVX #QS
Compute: #NVDA #AMD #QCOM #GOOGL #META #AMZN
Software: #U #PLTR #ZBRA
Builders: #TSLA #TER #SYM #ISRG #PRCT #KTOS #AVAV

0 0 0 0

PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended

4 months ago

#PRCT PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

4 months ago

#PRCT #b9604144-dcf3-4a7f-9655-ed90dec06560 #coveragefilings

Origin | Interest | Match

0 0 0 0

Jupiter Endovascular Closes Oversubscribed Series B Financing, Surpassing $40 Million Target Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.

5 months ago

#ISRG #PRCT Jupiter Endovascular Closes Oversubscribed Series B Financing, Surpassing $40 Million Target

www.stocktitan.net/news/ISRG/jupiter-endova...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Procept (PRCT) Q2 Revenue Jumps 48% | The Motley Fool

#PRCT #418aa646-1391-4308-b027-22af67db3131 #data-news

Origin | Interest | Match

0 0 0 0

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance PROCEPT BioRobotics (Nasdaq: PRCT) reported strong Q2 2025 financial results with total revenue of $79.2 million, up 48% year-over-year. The company's U.S. revenue grew 46% to $69.6 million, driven by system sales and increased handpiece revenue. International revenue surged 69% to $9.6 million.Key highlights include 51 new U.S. robotic system sales and an expanded U.S. install base of 595 systems. Gross margin improved to 65% from 59% year-over-year. The company increased its 2025 revenue guidance to $325.5 million, representing 45% growth. Additionally, PROCEPT announced the appointment of Larry Wood as CEO, effective September 2, 2025.

7 months ago

#PRCT PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy PROCEPT BioRobotics (Nasdaq: PRCT) announced a significant milestone in its WATER IV Prostate Cancer Trial, with three successful prostate cancer procedures completed at an Ambulatory Surgery Center (ASC) using Aquablation® therapy. The procedures were performed by Dr. Rahul Mehan in Scottsdale, Arizona.The FDA-approved IDE clinical study aims to compare Aquablation® therapy with radical prostatectomy for treating localized prostate cancer (Grade Group 1 to 3). Aquablation therapy utilizes a robotically-controlled waterjet for targeted prostate tissue removal, while radical prostatectomy involves complete prostate removal.This milestone demonstrates the potential for treating early-stage prostate cancer in an ASC setting, suggesting a more scalable and cost-effective care model for prostate cancer treatment.

7 months ago

#PRCT Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy

www.stocktitan.net/news/PRCT/ambulatory-sur...

0 0 0 0

Being Exponential | Luke Lango

@beingexponential.bsky.social

7 months ago

two retro-styled robots in a serene outdoor scene. the robots have rounded heads with circular eyes, rectangular mouth plates, and small antennae. their bodies feature red cross symbols, suggesting a medical theme. muted beige, green, and orange hues dominate their design. behind them, soft hills, sparse trees, and cloudy skies blend into a distant geometric structure resembling castle walls. the overall aesthetic combines vintage robotics with a calming, slightly whimsical landscape.

My best friend’s wife just had a pretty critical surgery very successfully performed by a Da Vinci robot.

And they say the #robots aren’t here…
#ISRG #PRCT #TSLA #SYM

0 0 0 0

Medicare Breakthrough: Aquablation Therapy Secures Category I Status, Matches TURP Reimbursement for BPH Treatment New Medicare Category I code elevates Aquablation's status in BPH treatment landscape. Compare proposed $540 reimbursement rate vs TURP's $529. See full payment details.

8 months ago

#PRCT Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

www.stocktitan.net/news/PRCT/aquablation-th...

0 0 0 0

Breakthrough BPH Treatment: Experts Reveal Long-Term Aquablation Results at Major Urology Conference New clinical data reveals Aquablation's durability in BPH treatment. Expert surgeons showcase HYDROS system outcomes and WATER IV study findings. Get insights.

10 months ago

#PRCT PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

PROCEPT Crushes Q1 Expectations: 55% Revenue Growth, International Sales Double, 2025 Guidance Raised Strong Q1 shows 61% US consumables growth and doubled international sales. See how PROCEPT's robotic surgery expansion drives record-breaking performance. Get analysis.

10 months ago

#PRCT PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

Leading Urologists Join PROCEPT BioRobotics Leadership for Exclusive Investor Insights Top urologists and executive team to share clinical perspectives and company updates. Live webcast available. Expert panel features USC Urology and KC Urology leaders.

11 months ago

#PRCT PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

New Clinical Data: Aquablation Reduces Sexual Side Effects by 80% vs Traditional Prostate Treatment Landmark WATER III trial reveals Aquablation therapy significantly reduces sexual dysfunction while matching symptom relief of laser treatment. See full efficacy data.

11 months ago

#PRCT WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

www.stocktitan.net/news/PRCT/water-iii-rand...

0 0 0 0

PROCEPT BioRobotics Unveils Double Header: Q1 Earnings and Star-Studded Investor Day at Major Urology Conference Leading urologists join PROCEPT's leadership to showcase innovations at AUA 2025. Special investor presentation plus Q1 earnings call offer comprehensive business insights.

1 year ago

#PRCT PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

PROCEPT BioRobotics Earnings: 57% Revenue Surge Despite Saline Shortage - Can Growth Continue? Q4 revenue reached $68.2M with 60 new US systems sold despite saline shortage challenges. 2025 guidance projects $320M revenue with improving margins.

1 year ago

#PRCT PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FUBO, #ARBE, #QBTS, #CLMT, #PRCT

#OptionFlow #OptionsTrading #Trading

1 0 0 0

Spruce Point Issues Stark Warning on PROCEPT BioRobotics, Questions $4.7B Valuation Short-seller report targets PROCEPT's BPH treatment market position, forecasting 30-60% downside risk. Analysis disputes addressable market claims and challenges Aquablation growth prospects.

1 year ago

#PRCT Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)

www.stocktitan.net/news/PRCT/spruce-point-c...

0 0 0 0

1 year ago

#PRCT PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024

www.stocktitan.net/news/PRCT/procept-bio-ro...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #PRCT ) Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #PRCT ) PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #PRCT ) PROCEPT BioRobotics Announces FDA Clearance of the HYDROS(TM) Robotic System, the Next-Generation, AI-Powered Platform for Aquablation Therapy

#StockMarket #News

1 0 0 0

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RIG, #S, #PRCT, #NDAQ, #ACB

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RIG 19.3x
2. #S 7.7x
3. #PRCT 3.6x
4. #NDAQ 3.4x
5. #ACB 2.6x

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#EH, #IBRX, #ALB, #DNA, #PRCT

#OptionFlow #OptionsTrading #Trading

0 0 0 0